NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its third-quarter 2009 net loss increased 13 percent as the firm rolled out its microRNA-based tests, which it expects will provide a stream of revenues during 2010.

The Rehovot, Israel-based firm did not report any revenues for the third quarters of 2009 or 2008. Its marketing partners recently introduced the firm's first three tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.